Sjögren's syndrome and lymphoma development

Current Immunology Reviews

Volumn 3, Issue 4, 2007, Pages 289-296

  Dong, Lingli ^a,b   Masaki, Yasufumi ^a   Tanaka, Masao ^a   Fukushima, Toshihiro ^a   Okazaki, Toshiro ^c   Umehara, Hisanori ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Lymphoma; Lymphoproliferative disease; Sj gren's syndrome

Indexed keywords

CD27 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CLADRIBINE; CYTOKINE; FC RECEPTOR; HYBRID PROTEIN; PROTEIN P53; RITUXIMAB;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CLINICAL EXAMINATION; CLONAL VARIATION; COHORT ANALYSIS; ENVIRONMENTAL EXPOSURE; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LABORATORY TEST; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MOLECULAR BIOLOGY; MUTAGENESIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SJOEGREN SYNDROME; TUMOR VIRUS; VIRUS INFECTION;

EID: 38349176289     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339507783334200     Document Type: Review

References (74)

1. Dafni UG, Tzioufas AG, Staikos P, Skopouli FN, Moutsopoulos HM. Prevalence of Sjogren's syndrome in a closed rural community. Ann Rheum Dis 1997; 56: 521-5.
2. Bredberg A, Henriksson G, Larsson A, Manthorpe R, Sallmyr A. Sjogren's syndrome and the danger model. Rheumatology (Oxford) 2005; 44: 965-70.
3. Bolstad AI, Eiken HG, Rosenlund B, Alarcon-Riquelme ME, Jonsson R. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum 2003; 48: 174-85.
4. Downie-Doyle S, Bayat N, Rischmueller M, Lester S. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome. Arthritis Rheum 2006; 54: 2434-40.
5. Kaschner S, Hansen A, Jacobi A, et al. Immunoglobulin Vlambda light chain gene usage in patients with Sjogrens syndrome. Arthritis Rheum 2001; 44: 2620-32.
6. Rolink AG, Melchers F. BAFFled B cells survive and thrive: roles of BAFF in B-cell development. Curr Opin Immunol 2002; 14: 266-75.
7. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109: 59-68.
8. von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995; 24: 323-58.
9. Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005; 52: 1185-95.
10. Fox RI. Sjogren's syndrome. Lancet 2005; 366: 321-31.
11. Talal N, Bunim JJ. The Development of Malignant Lymphoma in the Course of Sjoegren's Syndrome. Am J Med 1964; 36: 529-40.
12. Kassan SS, Thomas TL, Moutsopoulos RM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 888-92.
13. Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2006; 45: 1012-5.
14. Zufferey P, Meyer OC, Grossin M, Kahn MF. Primary Sjogren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS Scand J Rheumatol 1995; 24: 342-5.
15. Valesini G, Priori R, Bavoillot D, et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol 1997; 24: 2376-80.
16. Kauppi M, Pukkala E, Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997; 8: 201-4.
17. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796-803.
18. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337-44.
19. Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjogren's syndrome. Semin Arthritis Rheum 1998; 28: 80-7.
20. Kamel OW, van de Rijn M, Hanasono MM, Warnke RA. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma 1995; 16: 363-8.
21. Royer B. Cazals-Hatern D, Sibilia J, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997; 90: 766-75.
22. Isaacson PG, Spencer J. Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology 1987; 11: 445-62.
23. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 1999; 42: 1765-72.
24. Tonami H, Matoba M, Kuginuki Y, et al. Clinical and imaging findings of lymphoma in patients with Sjogren syndrome. J Comput Assist Tomogr 2003; 27: 517-24.
25. Pavlidis NA, Drosos AA, Papadimitriou C, Talal N, Moutsopoulos HM. Lymphoma in Sjogren's syndrome. Med Pediatr Oncol 1992; 20: 279-83.
26. Saito M, Fukuda T, Shiohara T, Homori M. Angioimmunoblastic T-cell lymphoma: a relatively common type of T-cell lymphoma in Sjogren's syndrome. Clin Exp Rheumatol 2005; 23: 888-90.
27. Voulgarelis M, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome. Isr Med Assoc J 2001; 3: 761-6.
28. Youinou P, Pers JO, Saraux A, Pennec YL. Viruses contribute to the development of Sjogren's syndrome. Clin Exp Immunol 2005; 141: 19-20.
29. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthhtis Rheum 2002; 46: 741-7.
30. Dorner T, Lipsky PE. Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjogren's syndrome. Arthritis Res 2002; 4: 360-71.
31. Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy--is there an association? Scand J Rheumatol 2001; 30: 185-8.
32. Masaki Y, Sugai S. Lymphoproliferative disorders in Sjogren's syndrome. Autoimmun Rev 2004; 3: 175-82.
33. Mackay IR, Rose NR. Autoimmunity and lymphoma: tribulations of B cells. Nat Immunol 2001; 2: 793-5.
34. Nakamura H, Kawakami A, Tominaga M, et al. Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjogren's syndrome. Lab Invest 1999; 79: 261-9.
35. Gottenberg JE, Lavie F, Abbed K, et al. CD4 CD25high regulatory T cells are not impaired in patients with primary Sjogren's syndrome. J Autoimmun 2005; 24: 235-42.
36. Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome. Arthritis Rheum 2002; 46: 2730-41.
37. Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002; 46: 2160-71.
38. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001; 167: 3610-8.
39. Delaleu N, Jonsson R, Koller MM. Sjogren's syndrome. Eur J Oral Sci 2005; 113: 101-13.
40. Pillemer SR. Lymphoma and other malignancies in primary Sjogren's syndrome. Ann Rheum Dis 2006; 65: 704-6.
41. Dorner T, Hansen A, Jacobi A, Lipsky PE. Immunglobulin repertoire analysis provides new insights into the immunopathogenesis of Sjogren's syndrome. Autoimmun Rev 2002; 1: 119-24.
42. Sugai S, Saito I, Misaki Y, et al. Rearrangement of the rheumatoid factor-related germline gene Vg and bcl-2 expression in lymphoproliferative disorders in patients with Sjogren's syndrome. Clin Immunol Immunopathol 1994; 72: 181-6.
43. Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren's syndrome) begin as nonmalignant antigen-selected expansions. Blood 1998; 91: 1864-72.
44. Chen X, Sugai S, Nakasaki S, Ogawa Y, Takeshita S Rheumatoid factor idiotypes in patients with Sjogren's syndrome. Nihon Rinsho Meneki Gakkai Kaishi 1996; 19: 468-76.
45. Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, van Noesel CJ. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005; 201: 1229-41.
46. Nishimura M, Miyajima S, Okada N. Salivary gland MALT lymphoma associated with Helicobacter pylori infection in a patient with Sjogren's Syndrome. J Dermatol 2000; 27: 450-2.
47. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 342: 571-4.
48. Savio A, Franzin G, Wotherspoon AC, et al. Diagnosis and post-treatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both? Blood 1996; 87: 1255-60.
49. King PD, McMurray RW, Becherer PR. Sjogren's syndrome without mixed cryoglobuilinemia is not associated with hepatitis C virus infection. Am J Gastroenterol 1994; 89: 1047-50.
50. Ramos-Casals M, la Civita L, de Vita S, et al. Characterization of B cell lymphoma in patients with Sjogren's syndrome and hepatitis C virus infection. Arthritis Rheum 2007; 57: 161-70.
51. Mariette X. Lymphomas complicating Sjogren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 2001; 60: 1007-10.
52. De Re V, De Vita S, Gasparotto D, et al. Salivary gland B cell lymphoproliferative disorders in Sjogren's syndrome present a restricted use of antigen receptor gene segments sunilar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. Eur J Immunol 2002; 32: 903-10.
53. Klussmann JP, Wagner M, Guntinas-Lichius O, Muller A. Detection of HHV-8 sequences and antigens in a MALT lymphoma associated with Sjogren's syndrome. J Oral Pathol Med 2003; 32: 243-5.
54. Tapinos NI, Polihronis M, Moutsopoulos HM. Lymphoma development in Sjogren's syndrome: novel p53 mutations. Arthritis Rheum 1999; 42: 1466-72.
55. Mariette X, Sibilia J, Delaforge C, Bengoufa D, Brouet JC, Soussi T. Anti-p53 antibodies are rarely detected in serum of patients with rheumatoid arthritis and Sjogren's syndrome. J Rheumatol 1999; 26: 1672-5.
56. Du M, Peng H, Singh N, Isaacson PG, Pan L. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 1995; 86: 4587-93.
57. Pisa EK, Pisa P, Kang HI, Fox RI. High frequency of t(14; 18) translocatien in salivary gland lymphomas from Sjogren's syndrome patients. J Exp Med 1991; 174: 1245-50.
58. Guo K, Major G, Foster H, et al. Defective repair of O6-methylguanine-DNA in primary Sjogren's syndrome patients predisposed to lymphoma. Ann Rheum Dis 1995; 54: 229-32.
59. Mitsias DI, Tzioufas AG, Veiopoulou C, et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp, Inummol 2002; 128: 562-8.
60. De Vita S, Boiocchi M, Sorrentino D, et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome. Arthritis Rheum 1997; 40: 318-31.
61. Schwartz RS. Shattuck lecture: Diversity of the immune repertoire and immunoregulation. N EngI J Med 2003; 348: 1017-26.
62. Dong L, Masaki Y, Takegami T, et al. Clonality analysis of lymphoproliferative disorders in patients with Sjogrens syndrome. Clin Exp Immunol 2007; 150: 279-84.
63. Diss TC, Peng H, Wotherspoon AC, Pan L, Speight PM, Isaacson PG. Brief report: a single neoplastic clone in sequential biopsy specimens from a patient with primary gastric-mucosa-associated lymphoid-tissue lymphoma and Sjogren's syndrome. N Engl J Med 1993; 329: 172-5.
64. Pablos JL, Carreira PE, Morillas L, Montalvo G, Ballestin C, Gomez-Reino JJ. Clonally expanded lymphocytes in the minor salivary glands of Siogren's syndrome patients without lymphoproliferative disease. Arthritis Rheum 1994; 37: 1441-4.
65. Lasota J, Miettinen MM. Coexistence of different B-cell clones in consecutive lesions of low-grade MALT lymphoma of the salivary gland in Sjogren's disease. Mod Pathol 1997; 10: 872-8.
66. Jordan R, Diss TC, Lench NJ, Isaacson PG, Speight PM. Immunoglobulin gene rearrangements in lymphoplasmacytic infiltrates of labial salivary glands in Sjogren's syndrome. A possible predictor of lymphoma development. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79: 723-9.
67. Aiello A, Du MQ, Diss TC, et al. Simultaneous phenotypically distinct but clonally identical mucosa-associated lymphoid tissue and follicular lymphoma in a patient with Sjogren's syndrome. Blood 1999; 94: 2247-51.
68. Gellrich S, Rutz S, Borkowski A, et al. Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjogren's syndrome. Arthritis Rheum 1999; 42: 240-7.
69. Gasparotto D, De Vita S, De Re V, et al. Extrasalivary lymphoma development in Sjogren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum 2003; 48: 3181-6.
70. Hansen A, Reiter K, Pruss A, et al. Dissemination of a Sjogren's syndrome-associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements. Arthritis Rheum 2006; 54: 127-37.
71. Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford) 2004; 43: 1050-3.
72. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007; 66: 351-7.
73. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005; 8: 243-65.
74. Kalled SL, Ambrose C, Hsu YM. BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders. Expert Opin Ther Targets 2003; 7: 115-23.